Journey Medical (DERM) Return on Capital Employed (2021 - 2026)
Journey Medical's (DERM) quarterly Return on Capital Employed came in at 11.48% in Q1 2026, up 483.0% YoY from 1.97% in Q1 2025, and up 26.33% on a QoQ basis from 15.58% in Q4 2025.
Journey Medical (DERM) Return on Capital Employed (2021 - 2026) Analysis & Trends
Journey Medical (DERM) has 6 years of Return on Capital Employed data on file, last reported at 11.48% in Q1 2026.
- Quarterly Return on Capital Employed rose 483.0% year-over-year to 11.48% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.48% (up 483.0% YoY) and the FY2025 annual result came in at 16.35%, up 1518.0% from the prior year.
- Return on Capital Employed improved to 11.48% in Q1 2026, from 15.58% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 6.69% in Q2 2024 to a low of 251.26% in Q2 2023.
- A 5-year average of 51.82% and a median of 37.0% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed sank 19918 bps — and 2024, when it jumped 25795 bps.
- Tracing DERM's Return on Capital Employed over 5 years: stood at 69.1% in 2022, then surged by 90 bps to 7.02% in 2023, then slumped by 427 bps to 37.0% in 2024, then jumped by 58 bps to 15.58% in 2025, then increased by 26 bps to 11.48% in 2026.
- The last three Return on Capital Employed figures came in at 11.48% (Q1 2026), 15.58% (Q4 2025), and 12.64% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Journey Medical | 208.68 Mn | 183.03 Mn | 12.37 Mn | -6.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.12% |
| Mar 31, 2026 | -11.48% |
| Dec 31, 2025 | -15.58% |
| Sep 30, 2025 | -12.64% |
| Jun 30, 2025 | -16.11% |
| Mar 31, 2025 | -16.31% |
| Dec 31, 2024 | -37.00% |
| Sep 30, 2024 | -57.59% |
| Jun 30, 2024 | 6.69% |
| Mar 31, 2024 | -7.94% |
| Dec 31, 2023 | -7.02% |
| Sep 30, 2023 | -51.57% |
| Jun 30, 2023 | -251.26% |
| Mar 31, 2023 | -153.29% |
| Dec 31, 2022 | -69.10% |
| Sep 30, 2022 | -53.11% |
| Jun 30, 2022 | -52.07% |
| Mar 31, 2022 | -75.54% |
| Dec 31, 2021 | -83.93% |